Single High Dose of Liposomal Amphotericin B in Human Immunodeficiency Virus/AIDS-Related Disseminated Histoplasmosis: A Randomized Trial
Clinical Infectious Diseases · 13.10.2023 · 77 (8) · 1126-1132
DOI: 10.1093/cid/ciad313 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 26.05.2023. Verfasst von Alessandro C Pasqualotto und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Post-Graduation Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Br…. Hauptthemen laut MEDLINE: Histoplasmosis, Acquired Immunodeficiency Syndrome, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Histoplasmosis is a major AIDS-defining illness in Latin America. Liposomal amphotericin B (L-AmB) is the drug of choice for treatment, but access is restricted due to the high drug and hospitalization costs of the conventional long regimens.
Methods
Prospective randomized multicenter open-label trial of 1- or 2-dose induction therapy with L-AmB versus control for disseminated histoplasmosis in AIDS, followed by oral itraconazole therapy. We randomized subjects to: (i) single dose 10 mg/kg of L-AmB; (ii) 10 mg/kg of L-AmB on D1, and 5 mg/kg of L-AmB on D3; (iii) 3 mg/kg of L-AmB daily for 2 weeks (control). The primary outcome was clinical response (resolution of fever and signs/symptoms attributable to histoplasmosis) at day 14.
Results
A total of 118 subjects were randomized, and median CD4+ counts, and clinical presentations were similar between arms. Infusion-related toxicity, kidney toxicity at multiple time-points, and frequency of anemia, hypokalemia, hypomagnesemia, and liver toxicity were similar. Day 14 clinical response was 84% for single-dose L-AmB, 69% 2-dose L-AmB, and 74% for control arm (P = .69). Overall survival on D14 was 89.0% (34/38) for single-dose L-AmB, 78.0% (29/37) for 2-dose L-AmB, and 92.1% (35/38) for control arm (P = .82).
Conclusions
One day induction therapy with 10 mg/kg of L-AmB in AIDS-related histoplasmosis was safe. Although clinical response may be non-inferior to standard L-AmB therapy, a confirmatory phase III clinical trial is needed. A single induction dose would markedly reduce drug-acquisition costs (>4-fold) and markedly shorten and simplify treatment, which are key points in terms of increased access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine and Post-Graduation Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
- Infectious Diseases and Internal Medicine Services, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil.
- Infectious Diseases Service, Hospital de Doenças Tropicais, Goiânia, Brazil.
- Department of Research and Education, Pontifícia Universidade Católica de Goiás, Goiânia, Brazil.
- Infectious Diseases Service, Hospital São José de Doenças Infecciosas, Fortaleza, Brazil.
- Department of Public Health, Federal University of Ceará, Fortaleza, Brazil.
ORCID-Profile: Alessandro C Pasqualotto
Zitieren
APA
Pasqualotto, A. C., Lana, D. D., Godoy, C. S. M., Leitão, T. D. M. J. S., Bay, M. B., Damasceno, L. S., Soares, R. B. A., Kist, R., Silva, L. R., Wiltgen, D., Melo, M., Guimarães, T. F., Guimarães, M. R., Vechi, H. T., de Mesquita, J. R. L., Monteiro, G. R. G., Adenis, A., Bahr, N. C., Spec, A., …, & Falci, D. R. (2023). Single High Dose of Liposomal Amphotericin B in Human Immunodeficiency Virus/AIDS-Related Disseminated Histoplasmosis: A Randomized Trial. Clinical Infectious Diseases, 77(8), 1126-1132. https://doi.org/10.1093/cid/ciad313
Vancouver
Pasqualotto AC, Lana DD, Godoy CSM, Leitão TDMJS, Bay MB, Damasceno LS, et al. Single High Dose of Liposomal Amphotericin B in Human Immunodeficiency Virus/AIDS-Related Disseminated Histoplasmosis: A Randomized Trial. Clinical Infectious Diseases. 2023;77(8):1126-1132. doi:10.1093/cid/ciad313
BibTeX
@article{Pasqualotto2023,
author = {Pasqualotto, Alessandro C and Lana, Daiane Dalla and Godoy, Cassia S M and Leitão, Terezinha do Menino Jesus Silva and Bay, Monica B and Damasceno, Lisandra Serra and Soares, Renata B A and Kist, Roger and Silva, Larissa R and Wiltgen, Denusa and Melo, Marineide and Guimarães, Taiguara F and Guimarães, Marilia R and Vechi, Hareton T and de Mesquita, Jacó R L and Monteiro, Gloria Regina de G and Adenis, Antoine and Bahr, Nathan C and Spec, Andrej and Boulware, David R and Israelski, Dennis and Chiller, Tom and Falci, Diego R},
title = {Single High Dose of Liposomal Amphotericin B in Human Immunodeficiency Virus/AIDS-Related Disseminated Histoplasmosis: A Randomized Trial},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {77},
number = {8},
pages = {1126--1132},
doi = {10.1093/cid/ciad313}
}
EUVIMED